ADDLIFE AB B
AddLife AB (publ), together with its subsidiaries, provides equipment, consumables, and reagents primarily to healthcare sector, research, colleges, and universities, as well as the food and pharmaceutical industries. The company operates through Labtech and Medtech segments. The Labtech segment offers products, solutions, and services in the areas of diagnostics, and biomedical research and labo… Read more
ADDLIFE AB B (1AD1) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, ADDLIFE AB B (1AD1) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
ADDLIFE AB B - Net Assets Trend (None–None)
This chart illustrates how ADDLIFE AB B's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ADDLIFE AB B (None–None)
The table below shows the annual net assets of ADDLIFE AB B from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to ADDLIFE AB B's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
ADDLIFE AB B Competitors by Market Cap
The table below lists competitors of ADDLIFE AB B ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
AEON MALL CO. LTD.
F:9DH
|
$1.50 Billion |
|
Intea Fastigheter B
ST:INTEA-B
|
$1.50 Billion |
|
Universal Technical Institute Inc
NYSE:UTI
|
$1.50 Billion |
|
Sharp Corporation
PINK:SHCAF
|
$1.50 Billion |
|
China Gold International Resources
PINK:JINFF
|
$1.50 Billion |
|
Blackbaud Inc
NASDAQ:BLKB
|
$1.50 Billion |
|
Polestar Automotive Holding UK PLC Class C-1 ADS (ADW)
NASDAQ:PSNYW
|
$1.50 Billion |
|
REA Group Limited
PINK:RPGRY
|
$1.49 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ADDLIFE AB B's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares ADDLIFE AB B's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently ADDLIFE AB B utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares ADDLIFE AB B's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $9,394,036,854
- Average return on equity (ROE) among peers: 4.98%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ADDLIFE AB B (1AD1) | €- | N/A | N/A | $1.50 Billion |
| Modern Dental Group Limited (1MD) | $2.36 Billion | 15.30% | 0.55x | $193.75 Million |
| SCHOTT Pharma AG & Co. KGaA (1SXP) | $709.04 Million | 17.68% | 0.69x | $479.33 Million |
| Alcon Inc. (2U3) | $19.26 Billion | 1.95% | 0.45x | $33.76 Billion |
| Shofu Inc. (69W) | $35.51 Billion | 8.83% | 0.23x | $216.48 Million |
| 7VG (7VG) | $176.36 Million | 14.92% | 1.12x | $684.88 Million |
| Bio-gate AG (BIG1) | $4.25 Million | -42.46% | 0.46x | $2.79 Million |
| Paul Hartmann AG (PHH2) | $690.37 Million | 10.65% | 0.81x | $783.58 Million |
| Sartorius AG VZO O.N. (SRT) | $497.08 Million | 9.76% | 1.56x | $6.27 Billion |
| Shandong Weigao Group Medical Polymer Company Limited (UK2) | $25.34 Billion | 8.16% | 0.37x | $1.26 Billion |